Ultrasound Microbubble Thrombolysis for Retinal Occlusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for retinal vascular occlusions, such as blockages in retinal veins and arteries, are limited as they either cause life-threatening complications or have limited success, with no definitive cure available, and existing methods like laser therapy only manage complications rather than addressing the blood clot directly.
Innovation Solution
The use of ultrasound combined with microbubbles, acting as contrast agents, to target and dissolve blood clots in the eye, allowing for precise drug delivery and activation at the site of the clot, minimizing systemic side effects and enabling direct visualization of the treatment process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic thrombolytic drugs are used to dissolve blood clots, then clot dissolution is achieved, but life-threatening complications occur
Solution Approach 1:
The patent applies local quality by using intravitreal injection to deliver thrombolytic drugs specifically to the eye, rather than systemic administration. This localized delivery ensures clot dissolution in the retinal vessel while avoiding systemic complications. The microbubble contrast agents further enhance this localization by accumulating at the site of blood flow obstruction, enabling precise targeted therapy.
Solution Approach 2:
The patent uses microbubble contrast agents as intermediaries to facilitate targeted drug delivery. These microbubbles serve as carriers that accumulate at the site of blood flow obstruction and can be activated by ultrasound to release the thrombolytic drug locally. This intermediary mechanism enables precise spatial control of drug release, resolving the contradiction between effective clot dissolution and avoiding systemic side effects.
2Object-affected harmful factors
If intravitreal injection of thrombolytic drugs is used, then localized treatment is achieved, but treatment effectiveness is limited
Solution Approach 1:
The patent employs mechanical vibration through ultrasound activation of microbubble contrast agents. The ultrasound waves cause the microbubbles to oscillate and rupture, releasing the encapsulated thrombolytic drug at the precise location of blood flow obstruction. This mechanical activation mechanism significantly enhances the treatment effectiveness compared to direct intravitreal injection alone, while maintaining localized delivery to avoid systemic side effects.
Solution Approach 2:
The patent replaces the mechanical injection system with an ultrasound-based activation system. Instead of relying solely on the mechanical force of intravitreal injection, the system uses ultrasound waves to activate microbubble carriers, which then release the drug through controlled mechanical rupture. This substitution enhances the precision and effectiveness of localized drug delivery.
3Ease of operation
If laser therapy is applied to treat retinal vascular occlusion, then complication management is achieved, but blood flow recovery is not improved
Solution Approach 1:
The patent extracts the primary treatment focus from complication management to direct clot dissolution. By using microbubble-enhanced ultrasound thrombolysis, the system directly targets and removes the blood clot causing the occlusion, rather than merely managing downstream complications. This extraction of the primary pathology enables both complication resolution and blood flow recovery simultaneously.
Solution Approach 2:
The patent introduces microbubble contrast agents as intermediaries to enhance the therapeutic effect. These microbubbles accumulate at the site of blood flow obstruction and, when activated by ultrasound, release thrombolytic drugs that directly dissolve the clot. This intermediary mechanism enables direct intervention in the primary disease process, achieving both complication management and blood flow recovery.
4Reliability
If targeted drug delivery to tumors is achieved, then treatment specificity is improved, but delivery mechanism complexity increases
Solution Approach 1:
The patent uses microbubble contrast agents as intermediaries to achieve targeted drug delivery to tumors. These microbubbles naturally accumulate at tumor sites through the enhanced permeability and retention effect, and when activated by ultrasound, release the encapsulated chemotherapeutic drugs locally. This intermediary approach achieves high treatment specificity while keeping the delivery mechanism relatively simple, as it leverages existing physiological tumor characteristics rather than requiring complex external targeting systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables a curative and long-lasting effect by directly dissolving blood clots, reducing systemic complications, and can be applied to various ocular diseases, including macular degeneration and retinoblastoma, with targeted drug delivery to tumors, effectively reversing occlusions and improving vision without harming other ocular structures.
Implementation Method 1
Ultrasound is then applied to the microbubbles to cause them to vibrate and return a unique echo
Implementation Method 2
Ultrasound combined with microbubbles, acting as contrast agents, to target and dissolve blood clots in the eye
Implementation Method 3
Ultrasound is then applied to the microbubbles to cause them to vibrate and return a unique echo
Implementation Method 4
The ability to image, while treating, vascular disease of the eye using targeted microbubbles is a great advantage permitting direct observation of the microbubbles and their targeted activation at the site of disease
Data Source
AI summary
The present disclosure described methods, systems, and techniques for applying contrast-enhanced ultrasound to locate areas of blockage within retinal vessels and to break up clots that are causing damage. In addition to identifying the damaged area, the researchers anticipate that the initial image may serve as a baseline for monitoring the effect of treatment on the vessel, which may be achieved in multiple ways. The vibration effect of the ultrasound itself may suffice to dislodge clots. The microbubbles may also be coated or filled with medication, with ultrasonic shock waves activating the coating or causing mini explosions to release the medicine. Loading the microbubbles with a therapeutic agent, visualizing their presence at the diseased site using the ultrasound diagnostic mode, and then activating the microbubbles to release their contents at the targeted lesion could be a powerful and effective way to reverse occlusion without harming other areas of the eye or body.